key: cord-0853082-4wly1s1p
authors: Kang, Ji Eun; Rhie, Sandy Jeong
title: Practice considerations on the use of investigational anti‐COVID‐19 medications: Dosage, administration and monitoring
date: 2020-06-11
journal: J Clin Pharm Ther
DOI: 10.1111/jcpt.13199
sha: bac71e473e4fa3930854b008de98df21b4b02cdc
doc_id: 853082
cord_uid: 4wly1s1p

WHAT IS KNOWN AND OBJECTIVE: Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID‐19. We comment on various drugs currently undergoing such trials to optimize their safe use. COMMENT: We describe medications used during early COVID‐19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient‐monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high‐dose intravenous immunoglobulin (IVIG). WHAT IS NEW AND CONCLUSION: Effective therapies are urgently needed to manage COVID‐19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up‐to‐date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.

More than 200 countries have been affected by COVID-19, and 3 110 369 confirmed patients and 226 294 deaths have been reported by the World Health Organization (WHO) as of 30 April 2020. 1, 2 The WHO interim guideline recommends symptomatic supportive care and administration of antiviral agents based on the severity of symptoms and risk factors. 3 The Infectious Diseases Society of America (IDSA) has published guidelines on managing patients with COVID-19, but their recommendation is associated with limited clinical trials. 4 Thus, investigational drugs have been prescribed for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 5 Lopinavir/ritonavir has been presented as an immediate oral (po) therapy for COVID-19. In Korea, lopinavir/ritonavir was the main medication administered during peak outbreaks before the global spread. 6 However, a study by Cao et al 7 challenges this result and cautions the use of this regimen because it lacks effectiveness.

Consequently, hydroxychloroquine may be considered the preferred choice; however, its antiviral mechanisms have not been fully investigated and it has even been found to worsen viral infections in animal studies. 8, 9 Remdesivir has shown positive results in vitro and in some clinical studies, and other clinical trial results are still expected. 10, 11 Here, we describe common investigational medications we have used on our patients, focusing on the practice aspects such as criteria of use, dose adjustments, formulations, adverse reactions and drug interactions to support clinical decision; however, these suggestions should be applied with clinical discretion.

Hydroxychloroquine and chloroquine are indicated for the prophylaxis and treatment of malaria. 12,13 Hydroxychloroquine is also a synthetic disease-modifying anti-rheumatic drug used to treat rheumatoid arthritis without significant adverse effects. 10 Both agents have demonstrated good in vitro activity against SARS-CoV-2 and reduce the duration of viral shedding. 8, 9 Synergistic viral load reduction was reported following co-treatment with hydroxychloroquine and azithromycin in patients with confirmed COVID-19 in early March of 2020. 14, 15 However, no human results have reported the successful treatment of patients with hydroxychloroquine and chloroquine single use. Moreover, chloroquine has been associated with paradoxically harmful effects in the treatment of Chikungunya virus infection in vivo. 16 

Several anecdotal dosing regimens have been used: (a) 400 mg daily for 5 days 17,18 ; (b) 400 mg twice daily (bid) on day 1, followed by 400 mg daily for 5 days 19 ; (c) 400 mg bid on day 1, followed by 200 mg bid for 4 days 20,21 ; (d) 600 mg bid on day 1, followed by 400 mg bid for 6 days 22 ; and (e) the US Food and Drug Administration (FDA) has recommended 800 mg on day 1, followed by 400 mg daily for 4-7 days for emergency use authorization (EUA). 13 Published regimens with azithromycin are as follows:

(f) 200 mg hydroxychloroquine three times a day (tid) for 10 days with 500 mg azithromycin daily on day 1, followed by 250 mg daily for 4 days 14 and (g) 600 mg hydroxychloroquine daily for 10 days with 500 mg azithromycin daily on day 1, followed by 250 mg daily for 4 days. 15 For patients who cannot swallow or have insufficient gastrointestinal functions, extemporaneous formulations of oral suspensions of 25 mg/mL hydroxychloroquine and 10 mg base/mL chloroquine are available as referenced. [23] [24] [25] These formulations are stable when refrigerated for 30 days and should be shaken well before use. Hydroxychloroquine is extensively metabolized by the liver. 26 Zinc supplementation may be considered along with chloroquine and hydroxychloroquine based on long-standing research reports that chloroquine is a zinc ionophore and zinc inhibits the coronavirus in vitro. 27, 28 Recent clinical trials to evaluate the effects of supplementation with zinc and vitamin C on COVID- 19 have also been planned. 29 Although no standard method of zinc supplementation has been established in the treatment of COVID-19, capsules containing 25 mg and 50 mg zinc acetate are available. 30

The usual chloroquine dosage for malaria treatment is 1000 mg orally, followed by 500 mg orally after 6-8 hours, and then 500 mg daily for 2 days. 13 In current COVID-19 trials, the doses being tested are (a) chloroquine diphosphate 450 mg bid on day 1, followed by 450 mg daily for 4 days as a low-dose regimen and (b) 600 mg bid for 10 days as a high-dose regimen. 12 In another trial with favipiravir, chloroquine was administered at (c) 500 mg bid on day 1, followed by 500 mg daily on day 2-3, and then 250 mg daily on day 4. 16, 31, 32 In a THDMS-COVID19 trial, chloroquine (d) 500 or 1000 mg/day was included in study arms added to darunavir with oseltamivir, ritonavir and favipiravir. 33 Under the US FDA EUA, the recommended dose is (e) 1000 mg chloroquine phosphate on day 1, followed by 500 mg daily for 4-7 days of the total treatment. 23 Chloroquine is less potent than hydroxychloroquine in vitro, but it may be used because hydroxychloroquine is unavailable in some countries or the supply is insufficient. 12 Patients with a glomerular filtration rate <10 mL/ min need a 50% dose reduction of chloroquine phosphate. 25 Each 200 mg of hydroxychloroquine sulphate is equivalent to 155 mg base, and 500 mg chloroquine phosphate is equivalent to 300 mg base. 12,34

The risk of arrhythmia at high cumulative doses necessitates caution in administering chloroquine because of its narrow therapeutic window, especially in patients with QTc >500 ms Furthermore, the electrocardiogram (ECG) may need to be monitored daily in patients with a high risk of cardiovascular disease.

Lopinavir/ritonavir was the main combination treatment used in Korea, and it significantly reduced the viral load. 35 However, it became an alternative option when hydroxychloroquine was contraindicated. 2 

Lopinavir/ritonavir 400/100 mg po bid, the dose for human immunodeficiency virus (HIV) treatment, has been investigated for the treatment of patients with COVID-19. 7 Investigational lopinavir/ ritonavir 400/100 mg bid with ribavirin was used for Middle East respiratory syndrome (MERS), 37 and lopinavir/ritonavir 10/2.5 mg/ kg plus favipiravir bid is under investigation in a clinical trial. 33 Thus, a 14-day treatment with these doses is being considered for patients with COVID-19. Patients who are unable to swallow tablets can take an oral solution that is commercially available as lopinavir/ritonavir 80/20 mg/mL. 31 The solution contains ethanol and propylene glycol, and therefore, it is incompatible with polyurethane feeding tubes. Thus, it may be administered using silicone and polyvinyl chloride feeding tubes. 38 Oral solutions should be refrigerated and used within 2 months when stored at room temperature. 38 

Approximately 14% of the participants were dropped from the trial because of gastrointestinal adverse events (6.8%-19.5%). Migraine (6.3%), hepatic injury (1%-29%), severe cutaneous eruptions and QTc prolongation have also been reported. 38 The potential for multiple drug interactions should be closely monitored because this agent potently inhibits cytochrome P450 (CYP) 3A and P-glycoprotein (Table 1 ). 38 

In preclinical trials, remdesivir demonstrated significant activity against the SARS-CoV-2 and a high genetic barrier to resistance. 10, 11 The manufacturer of remdesivir restricts its supply through the 'expanded access' programme for experimental COVID-19 treatments and 'compassionate use' for pregnant women and children. 39 This agent has shown promising results in vitro and the compassionate use trials showed a generally acceptable efficacy and safety, 6,39,40 but the protocol did not include a comparison group administered the standard of care at participating institutions. 41 Obtaining approval for this indication is highly anticipated based on the positive outcomes with patient in the trials; however, this agent would have very restricted use mainly for the most severely ill patients, as the ongoing trials have many exclusion criteria.

Remdesivir was tested at a dosage of 200 mg intravenously once on day 1, followed by 100 mg daily for 5-10 days or until respiratory symptoms improve. 42 The lyophilized solid containing 100 mg preservative-free remdesivir needs to be reconstituted with sterile water for injection and diluted with intravenous infusion fluids to a concentration of 100 mg/20 mL remdesivir. 43 No special training or equipment is required for drug administration.

One case of cardiac arrest and hypotension was reported during the trial (n = 673) in patients with Ebola viral infection. 44 Nausea, vomiting, gastroparesis and haematochezia with increased liver enzyme levels were reported by three patients during its compassionate use to treat COVID-19. 41 If possible, daily monitoring of renal and liver functions should be performed. 45 

A retrospective, observational study (n = 21) administered 400 mg tocilizumab, an interleukin (IL)-6 blocker, intravenously once to patients who had respiratory failure, shock or organ failure. 46 Although three patients received a subsequent dose, the benefit is unknown. 43 However, the potential benefit in decreasing mortality was evident as no deaths were reported out of 21 patients. 4

Other dosages used in trials are 8 mg/kg (maximum, 800 mg/dose) intravenously every 12 hours (q12h) or one 200 mg intravenous dose (up to two doses). Subcutaneous tocilizumab at two 162 mg doses followed by two more doses after 12 hours has been used in combination with hydroxychloroquine (400 mg q12h followed by 200 mg q12h orally for total of 7 days) and azithromycin (500 mg daily orally for 3 days). 47 It is stable at room temperature for 24 hours protected from light. 48 

All patients should be monitored for signs and symptoms of infection before, during, and after treatment. Cases of severe liver damage and intestinal perforation have been reported. 4, 46, 48 Although beneficial outcomes were observed in most patients, this should be interpreted cautiously as all patients in the study received routine treatment for 1 week and then tocilizumab was administered as an additional agent. The risk of neutropenia should be monitored.

Ciclesonide is an inhaled corticosteroid for the treatment of asthma, which has been a potential candidate for repurposing in the treatment of patients with MERS or COVID-19. 49 The dosage used in a current trial was 320 mcg q12h for 14 days. 50 Ironically, systemic corticosteroids are contraindicated in severe pneumonia caused by viruses such as MERS-CoV and SARS-CoV because they suppress the innate immune system, resulting in increased viral replication. This recommendation is the same as that of the IDSA COVID-19 guidelines except for acute respiratory distress syndrome. There are claims of decreased immunosuppressive effects of this agent with presumably fewer systematic effects because of the administration route. 50 The need for compliance to the recommended administration technique for this medication should be emphasized, if it becomes available for use based on trial results.

Another medication undergoing repurposing investigations for SARS-CoV-2 is niclosamide, an oral anthelmintic drug used worldwide at a single dose of 2 g/d. Niclosamide exerts anti-MERS activity, inhibits SARS-CoV replication and abolishes viral antigen synthesis in vitro, 51, 52 and therefore, is considered a possible treatment option. However, it is cytotoxic and has low absorption including low oral bioavailability (10%) and although efforts have been made to formulate derivatives to overcome these obstacles, its extensive clinical development as an antiviral agent may still be hindered. An

Increased the serum concentration of 'X'

'A/B' (strong CYP3A4 Inhibitor) may increase the serum concentration of 'X' 

The co-administration of high-dose intravenous immunoglobulin (IVIG) at 25 g/d for 5 days (body weight, 66 kg) with moxifloxacin was reported in a case series study. 54 Although no trials are currently recruiting, the IVIG doses used in protocols are in the range of 0.2-0.5 g kg −1 day −1 and the use of this agent is expected to be limited to patients in severe or critical conditions. 55 Other medications that are currently undergoing clinical trials with the associated dosages are baricitinib (4 mg/d orally) in combination with lopinavir/ritonavir (250 mg orally bid) 56 ; favipiravir (1600 mg bid on day 1, followed by 600 mg bid from day 2-7) with tocilizumab 57 ; arbidol (200mg orally three times), oseltamivir (75 mg orally bid) and lopinavir/ritonavir(500 mg orally bid) 58 ; and sarilumab (400 mg intravenously) with azithromycin and hydroxychloroquine. 59

The National Medical Center in Korea has played a pivotal role in managing infectious diseases since the MERS outbreak in 2015 and now serves as the headquarters for COVID-19 treatment operations. 60 At the beginning of the current outbreak of COVID-19

in January 2020, the guidelines we adopted for treating patients infected with SARS-CoV-2 were established based on the previous experience with the MERS outbreak, although clinical outcomes still need to be evaluated. 61 We hope that this paper will help clinicians understand, prioritize and monitor the drugs being used until results of clinical trials are available.

We thank all the pharmacists, clinicians and other healthcare professionals who are actively fighting against COVID-19.

The authors declare no conflicts of interest.

SJR designed, conceptualized and wrote the original draft, and reviewed and supervised the paper; JEK designed, wrote the original draft and edited and reviewed the paper; SJR was responsible for funding acquisition. 

World Health Organization

Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection

World Health Organization. International Clinical Trials Registry Platform (ICTRP)

Treatment recommendation of COVID-19 for healthcare professionals

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine sulfate health care provider fact sheet, version date 3/28/2020

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Paradoxical effect of chloroquine treatment in enhancing Chikungunya virus infection

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Hydroxychloroquine post exposure prophylaxis for coronavirus disease (COVID-19)

Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease (ORCHID)

Hydroxychloroquine to prevent Covid19 pneumonia

1?term=covid &cond=hydro xychl oroqu in-e&draw=3&rank=8

Effectiveness of hydroxychloroquine in Covid-19 patients (Covid)

Chloroquine phosphate health care provider fact sheet, version date 3/28/2020 2. FDA; 2020

Stability of chloroquine in an extemporaneously prepared suspension stored at three temperatures

Chloroquine is a zinc ionophore

Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

A study of quintuple therapy to treat COVID-19 infection (HAZDpaC). https://clini caltr ials.gov/ct2/show/NCT04 33451 2?term=zinc&cond=COVID -19&draw=2&rank=3

Chloroquine diphosphate for the treatment of severe acute respiratory syndrome secondary to SARS-CoV2 (CloroCOVID19)

Clinical trial of favipiravir tablets combine with chloroquine phosphate in the treatment of novel coronavirus pneumonia

Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquine for treatment of COVID19: a randomized control trial (THDMS-COVID19)

Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax

Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2

Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy)

Treatment of middle east respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Product information of KALETRA(R) oral capsules, oral solution

Three drugs fairly effective on novel coronavirus at cellular level

First case of 2019 novel coronavirus in the United States

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care. https:// clini caltr ials.gov/ct2/show/NCT04 29273 0?cond=Remde sivir &draw=2&rank=6

COVID-19) in the United States

A randomized, controlled trial of Ebola virus disease therapeutics

WHO R&D Blueprint -Ad-hoc expert consultation on clinical trials for ebola therapeutics

Effective treatment of severe COVID-19 patients with tocilizumab

Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19 (TOCOVID)

Product information of ACTEMRA(R)

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

A trial of ciclesonide in adults with mild COVID-19

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

Broad spectrum antiviral agent niclosamide and its therapeutic potential

A real-life experience on treatment of patients with COVID 19

High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease Open Forum

The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia

Baricitinib therapy in COVID-19

Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019

Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia. Accessed May1, 2020. 59. ClinicalTrials.gov. Efficacy of sarilumab + azithromycin + hydroxychloroquine, and sarilumab Alone, for adult patients hospitalized with moderate to severe COVID-19: a multicenter open-label 1:1 randomized controlled trial

Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea

Antiviral treatment guidelines for Middle East respiratory syndrome

Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring